SUNSHINE PHARMA (06887) announced its performance for 2025, with a net profit attributable to equity shareholders of approximately 272 million yuan, turning a loss into a profit year-on-year.

SUNSHINE PHARMA (06887) announced its performance in 2025, with revenue of approximately 4.815 billion yuan, a year-on-year increase of 19.81%. The gross profit was approximately 3.685 billion yuan, a year-on-year increase of 20.49%. The net profit attributable to equity shareholders of the company was approximately 272 million yuan, turning from a loss to a profit; earnings per share were 0.56 yuan. The announcement stated that the performance growth was mainly due to the significant increase in the incidence of influenza in the second half of 2025 compared to the previous year. The Group's core product, Oseltamivir Phosphate, as the preferred drug for the prevention and treatment of influenza, with precise efficacy and good brand reputation, saw a significant increase in market demand, achieving annual revenue of 3.576 billion yuan, a growth of 38.56% compared to 2024. At the same time, the Group adheres to a diversified market development strategy, continuously strengthens the construction of academic promotion system, optimizes channel layout and terminal coverage, enhances the market penetration rate, brand influence, and commercial value of core products, and other business pipelines also show good performance. In the future, the Group will focus on innovation and international development strategies while continuing to consolidate the commercial layout of existing product pipelines and solidify market advantages. On the one hand, it will accelerate the research and commercialization process of key products such as innovative drugs and biological preparations, continuously enrich the product pipeline, and inject strong momentum into the company's long-term performance growth. On the other hand, it will continue to deepen technical exchanges and strategic cooperation with leading international pharmaceutical companies, steadily promote the international layout of products and markets, and continuously enhance the company's long-term sustainable development capabilities and comprehensive competitiveness.